Martijn Kleijwegt
Directeur/Membre du Conseil chez OCULIS HOLDING AG
Fortune : 23 M $ au 31/05/2024
Profil
Martijn Kleijwegt is the founder of LSP Management Group BV and Life Sciences Partners BV, both founded in 1998.
He is currently a Managing Director at Life Sciences Partners II BV, a Director at AM-Pharma BV, The European Venture Capital Association, Vico Therapeutics BV, and Pharvaris GmbH.
He is also an Independent Director at Oculis Holding AG and a Partner at EQT Life Sciences Group BV.
Mr. Kleijwegt's former positions include Chairman at European Biotech Acquisition Corp., Managing Director at Lenildis Holding BV, and General Partner at Euroventures Benelux I BV.
He has also held various director positions at CelMed BioSciences, Inc., ISTO Technologies, Inc., Intrexon ActoBiotics NV, Movetis NV, Asoyia, Inc., OxThera AB, Natil Technologies Ltd., Orphazyme A, Eloxx Pharmaceuticals Ltd., Eloxx Pharmaceuticals, Inc., Kiadis Pharma BV, Prosensa Holding NV, Euroventures Ukraine Fund II LP, and EyeSense AG.
Mr. Kleijwegt received his undergraduate degree from the University of Amsterdam in 1983 and his graduate degree from the same university.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
OCULIS HOLDING AG
5,44% | 31/12/2023 | 1 997 302 ( 5,44% ) | 23 M $ | 31/05/2024 |
Postes actifs de Martijn Kleijwegt
| Sociétés | Poste | Début |
|---|---|---|
| OCULIS HOLDING AG | Directeur/Membre du Conseil | 03/03/2023 |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Directeur/Membre du Conseil | - |
Arvelle Therapeutics International GmbH
 Arvelle Therapeutics International GmbH BiotechnologyHealth Technology Arvelle Therapeutics GmbH provides treatment for patients suffering form CNS disorders. The company was founded by Ilise Lombrado, Gregory Mark Weinhoff and Mark Altmeyer and is headquartered in Basel, Switzerland. | Directeur/Membre du Conseil | 01/01/2019 |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Directeur/Membre du Conseil | 01/04/2016 |
EQT Life Sciences Group BV
 EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Private Equity Investor | 28/02/2022 |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Directeur/Membre du Conseil | - |
Life Sciences Partners II BV
 Life Sciences Partners II BV Investment ManagersFinance Life Sciences Partners II BV (LSP) focuses on the areas of human and non-human life sciences. LSP primarily invests in European biotechnology companies. | Corporate Officer/Principal | - |
Life Sciences Partners BV
 Life Sciences Partners BV Investment ManagersFinance Life Sciences Partners BV (LSP) focuses on the areas of human and non-human life sciences. LSP primarily invests in European biotechnology companies. | Directeur Général | 01/01/1998 |
| The European Venture Capital Association | Directeur/Membre du Conseil | - |
Anciens postes connus de Martijn Kleijwegt
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░ ░░░░░ ░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Martijn Kleijwegt
| University of Amsterdam | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| ELOXX PHARMACEUTICALS, INC. | Health Technology |
| PHARVARIS N.V. | Health Technology |
| ORPHAZYME A/S | Health Technology |
| OCULIS HOLDING AG | Health Technology |
| QIAGEN N.V. | Health Technology |
| Entreprise privées | 27 |
|---|---|
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Finance |
Lenildis Holding BV
 Lenildis Holding BV Financial ConglomeratesFinance Lenildis Holding BV operates as a investment holding company. The company is headquartered in Amsterdam, the Netherlands. | Finance |
Natil Technologies Ltd.
 Natil Technologies Ltd. Information Technology ServicesTechnology Services Natil Technologies Ltd. provides SAP technology and solutions. It focuses on outsourcing and offshore, systems integration & application development, software and consulting, and QA & training. The company was founded in 1999 and is headquartered in Tel Aviv, Israel. | Technology Services |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
Life Sciences Partners II BV
Life Sciences Partners II BV Investment ManagersFinance Life Sciences Partners II BV (LSP) focuses on the areas of human and non-human life sciences. LSP primarily invests in European biotechnology companies. | Finance |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Health Technology |
Life Sciences Partners BV
Life Sciences Partners BV Investment ManagersFinance Life Sciences Partners BV (LSP) focuses on the areas of human and non-human life sciences. LSP primarily invests in European biotechnology companies. | Finance |
| The European Venture Capital Association | |
Kiadis Pharma NV
 Kiadis Pharma NV Pharmaceuticals: MajorHealth Technology Kiadis Pharma NV engages in pharmaceutical development of cell-based immunotherapy products in the field of diseases of the blood building system. Its lead product is the ATIR101. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
CelMed BioSciences, Inc.
 CelMed BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Celmed BioSciences Inc. is a biopharmaceutical company. The company is engaged in developing breakthrough products to treat cancer. The company offers rational drug design and pharmacogenomic concepts to improve cancer patient care. Products of the company include Theralux and NB1011 which offers “Trojan horse solution' to treat cancer. The company is headquartered in Saint-Laurent, Canada. | Health Technology |
Movetis NV
 Movetis NV Pharmaceuticals: GenericHealth Technology Movetis NV operates as a pharmaceutical company, that focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, and paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company was founded in November 2006 and is headquartered in Turnhout, Belgium. | Health Technology |
Prosensa Holding NV
 Prosensa Holding NV BiotechnologyHealth Technology Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Health Technology |
Kiadis Pharma BV
 Kiadis Pharma BV Pharmaceuticals: MajorHealth Technology Kiadis Pharma BV operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products include: ATIR101 and ATIR201. The firm’s products are based on hematopoietic blood-forming stem cell transplants from donors. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Crucell NV
 Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Health Technology |
Vico Therapeutics BV
Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Health Technology |
EQT Life Sciences Group BV
EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Finance |
Euroventures Benelux I BV
 Euroventures Benelux I BV Investment ManagersFinance Euroventures Benelux I BV invests in life science companies located in the BeNeLux. The fund targets companies operating in the fields of drug development, therapeutics, diagnostics, technologies, medical devices, agriculture, clean technology, food, nutrition, and biofuels. It provides financing at all stages of a company's development from seed stage to pre-IPO capital requirements. It invests in both private and public companies. | Finance |
European Biotech Acquisition Corp.
 European Biotech Acquisition Corp. Financial ConglomeratesFinance European Biotech Acquisition Corp. is a blank check company which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on January 8, 2021 and is headquartered in Lausanne, Switzerland. | Finance |
Pharvaris GmbH
Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Health Technology |
Arvelle Therapeutics International GmbH
Arvelle Therapeutics International GmbH BiotechnologyHealth Technology Arvelle Therapeutics GmbH provides treatment for patients suffering form CNS disorders. The company was founded by Ilise Lombrado, Gregory Mark Weinhoff and Mark Altmeyer and is headquartered in Basel, Switzerland. | Health Technology |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
EyeSense AG
 EyeSense AG Medical SpecialtiesHealth Technology EyeSense AG develops novel continuous blood glucose monitoring systems for diabetes patients. The firm's continuous glucose monitoring (CGM) gives a sense of security to diabetic patients. The company was founded by Achim Müller in 2006 and is headquartered in Basel, Switzerland. | Health Technology |
Euroventures Ukraine Fund II LP
 Euroventures Ukraine Fund II LP Investment ManagersFinance EuroVentures Ukraine Fund II LP provides development and expansion capital to medium-sized Ukrainian companies. It acquires majority or significant minority interests. The fund targets the consumer services sector. | Finance |
Eloxx Pharmaceuticals Ltd.
 Eloxx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Eloxx Pharmaceuticals Ltd. provides biopharmaceutical research and development services. The firm specializes in the discovery, development, and commercialization of drug compounds for the treatment of genetic diseases. It focuses on the treatment of diseases caused by nonsense mutations, including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, and Tay-Sachs Hurler syndrome. Its focus areas encompass clinical drug development and target drugs discovery programs. The company was founded by Silvia Noiman and Shmuel Tuvia in 2013 and is headquartered in Herzliya, Israel. | Health Technology |
Rhein Biotech NV
 Rhein Biotech NV Miscellaneous Commercial ServicesCommercial Services Rhein Biotech NV developed and manufactured pharmaceutical drugs and vaccines. The company provided licenses to vaccines and biopharmaceutical products in the area of respiratory travel and hepatitis B/pediatric. Rhein Biotech was headquartered in Maastricht, the Netherlands. | Commercial Services |
ISTO Technologies, Inc.
 ISTO Technologies, Inc. Medical SpecialtiesHealth Technology ISTO Technologies, Inc. develops and markets clinical solutions for spinal therapy, sports medicine, and trauma. It develops biologic products to rebuild bone, and heal degenerated or damaged cartilage. The company was founded by Joseph Feder and Scott Gill in 1997 and is headquartered in St. Louis, MO. | Health Technology |
Asoyia, Inc.
 Asoyia, Inc. Agricultural Commodities/MillingProcess Industries Asoyia, Inc. was produced and sold soybeans. The company was founded in 2004 and was headquartered in Iowa City, IA. | Process Industries |
